Unveiling the NEFH+ malignant cell subtype: Insights from single-cell RNA sequencing in prostate cancer progression and tumor microenvironment interactions

BackgroundProstate cancer (PCa) is a multifactorial and heterogeneous disease, ranking among the most prevalent malignancies in men. In 2020, there were 1,414,259 new cases of PCa worldwide, accounting for 7.3% of all malignant tumors. The incidence rate of PCa ranks third, following breast cancer a...

Full description

Saved in:
Bibliographic Details
Main Authors: Jie Wang, Fu Zhao, Qiang Zhang, Zhou Sun, Zhikai Xiahou, Changzhong Wang, Yan Liu, Zongze Yu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1517679/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846114897729945600
author Jie Wang
Jie Wang
Fu Zhao
Qiang Zhang
Zhou Sun
Zhikai Xiahou
Changzhong Wang
Yan Liu
Zongze Yu
author_facet Jie Wang
Jie Wang
Fu Zhao
Qiang Zhang
Zhou Sun
Zhikai Xiahou
Changzhong Wang
Yan Liu
Zongze Yu
author_sort Jie Wang
collection DOAJ
description BackgroundProstate cancer (PCa) is a multifactorial and heterogeneous disease, ranking among the most prevalent malignancies in men. In 2020, there were 1,414,259 new cases of PCa worldwide, accounting for 7.3% of all malignant tumors. The incidence rate of PCa ranks third, following breast cancer and lung cancer. Patients diagnosed with high-grade PCa frequently present with existing or developing metastases, complicating their treatment and resulting in poorer prognoses, particularly for those with bone metastases. Utilizing single-cell RNA sequencing (scRNA-seq), we identified specific malignant cell subtypes that are closely linked to high-grade PCa. By investigating the mechanisms that govern interactions within the tumor microenvironment (TME), we aim to offer new theoretical insights that can enhance the prevention, diagnosis, and treatment of PCa, ultimately striving to improve patient outcomes and quality of life.MethodsData on scRNA-seq was obtained from the GEO database. The gene ontology and gene set enrichment analysis were employed to analyze differential expression genes. Using inferCNV analysis to identify malignant epithelial cells. We subsequently employed Monocle, Cytotrace, and Slingshot packages to infer subtype differentiation trajectories. The cellular communication between malignant cell subtypes and other cells was predicted using the CellChat package. Furthermore, we employed pySCENIC to analyze and identify the regulatory networks of transcription factors (TFs) in malignant cell subtypes. The MDA PCa 2b and VCap cell lines were employed to validate the analysis results through cellular functional experiments. In addition, a risk scoring model was developed to assess the variation in clinical characteristics, prognosis, immune infiltration, immune checkpoint, and drug sensitivity.ResultsA malignant cell subtype in PCa with high expression of NEFH was identified through scRNA-seq analysis. This subtype was situated at the differentiation terminal, exhibited a higher level of malignancy, and exhibited characteristics that were more prone to advanced tumor lesions. In addition, our research underscored the intricate interactions that exist within the TME, particularly the interaction between PTN secreted by this subtype and fibroblasts via the NCL receptor. This interaction may be closely associated with cancer-associated fibroblasts and tumor progression. Subsequently, we determined that the NEFH+ malignant cell subtype was significantly correlated with the TF IRX4. This TF is linked to a worse prognosis in PCa and may affect disease progression by regulating gene transcription. Our conclusions were additionally verified through cellular experiments. Furthermore, the prognostic model we developed demonstrated satisfactory predictive performance, with gene sets from the high NmRS group facilitating tumor progression and deterioration. The analysis of immune infiltration was instrumental in the development of clinical intervention strategies and patient prognosis.ConclusionBy examining the cellular heterogeneity of a unique NEFH+ malignant cell subtype within the PCa microenvironment, we were able to disclose their reciprocal interaction with disease progression. This offers a novel viewpoint on the diagnosis and treatment of PCa.
format Article
id doaj-art-a120031d6eb847cd94e7d2c3e540f5dd
institution Kabale University
issn 1664-3224
language English
publishDate 2024-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-a120031d6eb847cd94e7d2c3e540f5dd2024-12-20T06:29:29ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-12-011510.3389/fimmu.2024.15176791517679Unveiling the NEFH+ malignant cell subtype: Insights from single-cell RNA sequencing in prostate cancer progression and tumor microenvironment interactionsJie Wang0Jie Wang1Fu Zhao2Qiang Zhang3Zhou Sun4Zhikai Xiahou5Changzhong Wang6Yan Liu7Zongze Yu8Department of Urology, The Second People’s Hospital of Meishan City, Meishan, Sichuan, ChinaDepartment of Urology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, ChinaThe First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, ChinaDepartment of Urology, The Second People’s Hospital of Meishan City, Meishan, Sichuan, ChinaDepartment of Urology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, ChinaChina Institute of Sport and Health Science, Beijing Sport University, Beijing, ChinaDepartment of Urology, The First People’s Hospital of Jiangxia District, Wuhan, Hubei, ChinaDepartment of Urology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, ChinaDepartment of Urology, The Second People’s Hospital of Meishan City, Meishan, Sichuan, ChinaBackgroundProstate cancer (PCa) is a multifactorial and heterogeneous disease, ranking among the most prevalent malignancies in men. In 2020, there were 1,414,259 new cases of PCa worldwide, accounting for 7.3% of all malignant tumors. The incidence rate of PCa ranks third, following breast cancer and lung cancer. Patients diagnosed with high-grade PCa frequently present with existing or developing metastases, complicating their treatment and resulting in poorer prognoses, particularly for those with bone metastases. Utilizing single-cell RNA sequencing (scRNA-seq), we identified specific malignant cell subtypes that are closely linked to high-grade PCa. By investigating the mechanisms that govern interactions within the tumor microenvironment (TME), we aim to offer new theoretical insights that can enhance the prevention, diagnosis, and treatment of PCa, ultimately striving to improve patient outcomes and quality of life.MethodsData on scRNA-seq was obtained from the GEO database. The gene ontology and gene set enrichment analysis were employed to analyze differential expression genes. Using inferCNV analysis to identify malignant epithelial cells. We subsequently employed Monocle, Cytotrace, and Slingshot packages to infer subtype differentiation trajectories. The cellular communication between malignant cell subtypes and other cells was predicted using the CellChat package. Furthermore, we employed pySCENIC to analyze and identify the regulatory networks of transcription factors (TFs) in malignant cell subtypes. The MDA PCa 2b and VCap cell lines were employed to validate the analysis results through cellular functional experiments. In addition, a risk scoring model was developed to assess the variation in clinical characteristics, prognosis, immune infiltration, immune checkpoint, and drug sensitivity.ResultsA malignant cell subtype in PCa with high expression of NEFH was identified through scRNA-seq analysis. This subtype was situated at the differentiation terminal, exhibited a higher level of malignancy, and exhibited characteristics that were more prone to advanced tumor lesions. In addition, our research underscored the intricate interactions that exist within the TME, particularly the interaction between PTN secreted by this subtype and fibroblasts via the NCL receptor. This interaction may be closely associated with cancer-associated fibroblasts and tumor progression. Subsequently, we determined that the NEFH+ malignant cell subtype was significantly correlated with the TF IRX4. This TF is linked to a worse prognosis in PCa and may affect disease progression by regulating gene transcription. Our conclusions were additionally verified through cellular experiments. Furthermore, the prognostic model we developed demonstrated satisfactory predictive performance, with gene sets from the high NmRS group facilitating tumor progression and deterioration. The analysis of immune infiltration was instrumental in the development of clinical intervention strategies and patient prognosis.ConclusionBy examining the cellular heterogeneity of a unique NEFH+ malignant cell subtype within the PCa microenvironment, we were able to disclose their reciprocal interaction with disease progression. This offers a novel viewpoint on the diagnosis and treatment of PCa.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1517679/fullmulti-omicssingle-cell RNA sequencingprostate cancertumor heterogeneityprecision medicinedrug discovery
spellingShingle Jie Wang
Jie Wang
Fu Zhao
Qiang Zhang
Zhou Sun
Zhikai Xiahou
Changzhong Wang
Yan Liu
Zongze Yu
Unveiling the NEFH+ malignant cell subtype: Insights from single-cell RNA sequencing in prostate cancer progression and tumor microenvironment interactions
Frontiers in Immunology
multi-omics
single-cell RNA sequencing
prostate cancer
tumor heterogeneity
precision medicine
drug discovery
title Unveiling the NEFH+ malignant cell subtype: Insights from single-cell RNA sequencing in prostate cancer progression and tumor microenvironment interactions
title_full Unveiling the NEFH+ malignant cell subtype: Insights from single-cell RNA sequencing in prostate cancer progression and tumor microenvironment interactions
title_fullStr Unveiling the NEFH+ malignant cell subtype: Insights from single-cell RNA sequencing in prostate cancer progression and tumor microenvironment interactions
title_full_unstemmed Unveiling the NEFH+ malignant cell subtype: Insights from single-cell RNA sequencing in prostate cancer progression and tumor microenvironment interactions
title_short Unveiling the NEFH+ malignant cell subtype: Insights from single-cell RNA sequencing in prostate cancer progression and tumor microenvironment interactions
title_sort unveiling the nefh malignant cell subtype insights from single cell rna sequencing in prostate cancer progression and tumor microenvironment interactions
topic multi-omics
single-cell RNA sequencing
prostate cancer
tumor heterogeneity
precision medicine
drug discovery
url https://www.frontiersin.org/articles/10.3389/fimmu.2024.1517679/full
work_keys_str_mv AT jiewang unveilingthenefhmalignantcellsubtypeinsightsfromsinglecellrnasequencinginprostatecancerprogressionandtumormicroenvironmentinteractions
AT jiewang unveilingthenefhmalignantcellsubtypeinsightsfromsinglecellrnasequencinginprostatecancerprogressionandtumormicroenvironmentinteractions
AT fuzhao unveilingthenefhmalignantcellsubtypeinsightsfromsinglecellrnasequencinginprostatecancerprogressionandtumormicroenvironmentinteractions
AT qiangzhang unveilingthenefhmalignantcellsubtypeinsightsfromsinglecellrnasequencinginprostatecancerprogressionandtumormicroenvironmentinteractions
AT zhousun unveilingthenefhmalignantcellsubtypeinsightsfromsinglecellrnasequencinginprostatecancerprogressionandtumormicroenvironmentinteractions
AT zhikaixiahou unveilingthenefhmalignantcellsubtypeinsightsfromsinglecellrnasequencinginprostatecancerprogressionandtumormicroenvironmentinteractions
AT changzhongwang unveilingthenefhmalignantcellsubtypeinsightsfromsinglecellrnasequencinginprostatecancerprogressionandtumormicroenvironmentinteractions
AT yanliu unveilingthenefhmalignantcellsubtypeinsightsfromsinglecellrnasequencinginprostatecancerprogressionandtumormicroenvironmentinteractions
AT zongzeyu unveilingthenefhmalignantcellsubtypeinsightsfromsinglecellrnasequencinginprostatecancerprogressionandtumormicroenvironmentinteractions